- |||||||||| LM11A-31-BHS / PharmatrophiX
Trial completion, Trial completion date: Study of LM11A-31-BHS in Mild-moderate AD Patients (clinicaltrials.gov) - Sep 4, 2020
P1/2, N=242, Completed,
Active, not recruiting --> Completed | Trial completion date: Sep 2020 --> Jun 2020
- |||||||||| LM11A-31-BHS / PharmatrophiX
Enrollment closed, Trial completion date, Trial primary completion date: Study of LM11A-31-BHS in Mild-moderate AD Patients (clinicaltrials.gov) - Mar 5, 2020
P1/2, N=242, Active, not recruiting,
Active, not recruiting --> Completed | Trial completion date: Sep 2020 --> Jun 2020 Recruiting --> Active, not recruiting | Trial completion date: Oct 2019 --> Sep 2020 | Trial primary completion date: Oct 2019 --> Jun 2020
- |||||||||| rasagiline / Generic mfg.
[VIRTUAL] ALZHEIMER’S DRUG DEVELOPMENT PIPELINE: NOVEL TARGETS AND INNOVATIVE APPROACHES (Hall E) - Jan 6, 2020 - Abstract #AATADPD2020AAT_ADPD_54;
One novel combination approach consists of losartan, amlodipine, atorvastatin and exercise and rasagiline is an example of molecule with pleiotropic effects on dopamine and disease-biology pathways...Novel designs being integrated into AD drug development include basket trials, randomized withdrawal trials, serial parallel comparison designs, and platform trials. Conclusions Progress in development of agents with novel targets and novel approaches will accelerate drug development for AD, clarify the disease-biology, and contribute to the development of treatments and treatment combinations for different phases of AD.
- |||||||||| LM11A-31-BHS / PharmatrophiX
Enrollment change: Study of LM11A-31-BHS in Mild-moderate AD Patients (clinicaltrials.gov) - Apr 5, 2018
P1/2, N=180, Recruiting,
Conclusions Progress in development of agents with novel targets and novel approaches will accelerate drug development for AD, clarify the disease-biology, and contribute to the development of treatments and treatment combinations for different phases of AD. N=120 --> 180
|
